| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.13 | 0.04 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.04 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.04 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.04 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.075 | 0.04 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.085 | 0.05 |
| mRNA | sotrastaurin | CTRPv2 | pan-cancer | AAC | -0.085 | 0.05 |